Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab

J Dtsch Dermatol Ges. 2018 Oct;16(10):1263-1265. doi: 10.1111/ddg.13656. Epub 2018 Oct 1.

Authors

Costantino Ricci¹, Alessandro Pileri², Claudio Agostinelli¹, Francesca Ambrosi¹, Pier Luigi Zinzani¹, Elena Sabattini¹

Affiliations

¹ Department of Specialized, Diagnostic and Experimental Medicine, Hematopathology Unit, Bologna, Italy.
² Department of Specialized, Diagnostic and Experimental Medicine, Division of Dermatology, Bologna, Italy.

PMID: 30277017
DOI: 10.1111/ddg.13656

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents / adverse effects*
CD8-Positive T-Lymphocytes
Chronic Disease
Drug Eruptions / etiology
Female
Humans
Lymphoma, T-Cell, Cutaneous / chemically induced*
Pseudolymphoma / chemically induced*
Sezary Syndrome / drug therapy*
Skin Neoplasms / chemically induced
Skin Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
mogamulizumab